Skip navigation
Use este identificador para citar ou linkar para este item: http://repositorio.unb.br/handle/10482/40964
Arquivos associados a este item:
Não existem arquivos associados a este item.
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorRé, Ana Carolina S.-
dc.contributor.authorMartins, Jayanaraian F.-
dc.contributor.authorCunha Filho, Marcílio Sérgio Soares da-
dc.contributor.authorGelfuso, Guilherme Martins-
dc.contributor.authorAires, Carolina P.-
dc.contributor.authorGratieri, Taís-
dc.date.accessioned2021-05-20T14:09:39Z-
dc.date.available2021-05-20T14:09:39Z-
dc.date.issued2021-01-19-
dc.identifier.citationRÉ, Ana Carolina S. et al. New perspectives on the topical management of recurrent candidiasis. Drug Delivery and Translational Research, n.11, p.1568-1585, 2021. DOI: https://doi.org/10.1007/s13346-021-00901-0.pt_BR
dc.identifier.urihttps://repositorio.unb.br/handle/10482/40964-
dc.language.isoInglêspt_BR
dc.publisherSpringer Naturept_BR
dc.rightsAcesso Restritopt_BR
dc.titleNew perspectives on the topical management of recurrent candidiasispt_BR
dc.typeArtigopt_BR
dc.subject.keywordCandidíasept_BR
dc.subject.keywordReincidênciapt_BR
dc.subject.keywordBiofilmept_BR
dc.subject.keywordTecnologia farmacêuticapt_BR
dc.identifier.doihttps://doi.org/10.1007/s13346-021-00901-0pt_BR
dc.relation.publisherversionhttps://link.springer.com/article/10.1007%2Fs13346-021-00901-0pt_BR
dc.description.abstract1Candidiasis is a common opportunistic infection caused by fungi of the Candida genus that affects mainly mucocutaneous tissues (e.g., vaginal, oral, and mammary). This condition has been known for a long time; thus, innumerous topical and systemic treatments are already available on the market worldwide. Yet, recurrent superficial candidiasis (RSC) is an expected outcome, still lacking effective and convenient treatments. Although several individual conditions may contribute to disease recurrence, biofilms’ presence seems to be the main etiological factor contributing to antifungal resistance. More than proposing novel antifungal agents, current research seems to be focusing on improving the pharmaceutical technology aspects of formulations to address such a challenge. These include extending and improving intimate contact of drug delivery systems with the mucocutaneous tissues, increasing drug loading dose, and enhancing topical drug permeation. This review discusses the current understanding of the RSC and the use of pharmaceutical technology tools in obtaining better results. Even though several drawbacks of conventional formulations have been circumvented with the help of nano- or microencapsulation techniques and with the use of mucoadhesive formulation excipients, many challenges remain. In particular, the need to mask the unpalatable taste of formulations for the treatment of oral candidiasis, and the necessity of formulations with a “dryer” sensorial feeling and improved performances in providing higher bioavailability for the treatment of mammary and vaginal candidiasis.pt_BR
Aparece nas coleções:Artigos publicados em periódicos e afins

Mostrar registro simples do item Visualizar estatísticas



Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.